T2ND34 logo

Tandem Diabetes Care BOVESPA:T2ND34 Stock Report

Last Price

R$8.96

Market Cap

R$7.8b

7D

3.2%

1Y

-48.8%

Updated

23 May, 2025

Data

Company Financials +

Tandem Diabetes Care, Inc.

BOVESPA:T2ND34 Stock Report

Market Cap: R$7.8b

T2ND34 Stock Overview

Designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. More details

T2ND34 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Tandem Diabetes Care, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tandem Diabetes Care
Historical stock prices
Current Share PriceUS$8.96
52 Week HighUS$18.90
52 Week LowUS$6.35
Beta1.48
1 Month Changen/a
3 Month Changen/a
1 Year Change-48.80%
3 Year Change-60.35%
5 Year Changen/a
Change since IPO-78.72%

Recent News & Updates

Recent updates

Shareholder Returns

T2ND34BR Medical EquipmentBR Market
7D3.2%-3.2%-0.6%
1Y-48.8%1.9%4.6%

Return vs Industry: T2ND34 underperformed the BR Medical Equipment industry which returned 2.9% over the past year.

Return vs Market: T2ND34 underperformed the BR Market which returned 4.2% over the past year.

Price Volatility

Is T2ND34's price volatile compared to industry and market?
T2ND34 volatility
T2ND34 Average Weekly Movementn/a
Medical Equipment Industry Average Movement7.2%
Market Average Movement5.3%
10% most volatile stocks in BR Market9.8%
10% least volatile stocks in BR Market2.9%

Stable Share Price: T2ND34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine T2ND34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20062,650John Sheridanwww.tandemdiabetes.com

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body.

Tandem Diabetes Care, Inc. Fundamentals Summary

How do Tandem Diabetes Care's earnings and revenue compare to its market cap?
T2ND34 fundamental statistics
Market capR$7.78b
Earnings (TTM)-R$1.04b
Revenue (TTM)R$5.56b
1.4x
P/S Ratio
-7.5x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
T2ND34 income statement (TTM)
RevenueUS$982.95m
Cost of RevenueUS$469.64m
Gross ProfitUS$513.31m
Other ExpensesUS$697.18m
Earnings-US$183.87m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.76
Gross Margin52.22%
Net Profit Margin-18.71%
Debt/Equity Ratio228.2%

How did T2ND34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 00:40
End of Day Share Price 2025/05/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tandem Diabetes Care, Inc. is covered by 40 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Travis SteedBarclays
Matthew MiksicBarclays